Press Releases


US/EU collaboration brings resources and talent together to fight one of the world’s deadliest diseases.

Liverpool, UK, 21st March 2013: The PreDiCT-TB consortium and the Critical Path to TB Drug Regimens (CPTR) have signed a memorandum of understanding to coordinate the work in developing new and effective treatment regimens for tuberculosis (TB). This was facilitated by two of the world’s leading organisations advancing scientific breakthroughs that help accelerate drug approvals, the Innovative Medicines Initiative (IMI) and Critical Path Institute (C-Path).

TB remains one of the leading causes of death worldwide. Nearly nine million new cases of TB and 1.4 million deaths are reported each year. Standard TB treatment takes months with a multi-drug regimen, while treating drug-resistant strains—which are on the rise globally—may take two years.
“TB is a global killer, and it will take global solutions to defeat this insidious disease,” said Martha Brumfield, President and CEO of C-Path. “We are honoured to join with the IMI and bring our consortia together in a bold effort to accelerate effective treatments of TB.”

“There is an urgent need to develop shorter, more effective treatment regimens to tackle this deadly disease,’ said Michel Goldman, IMI Executive Director. ‘By coordinating their activities, PreDiCT-TB and CPTR will ensure that the resources invested by both the pharmaceutical companies and the public sector are optimally used to achieve the projects’ ambitious goals.”

PreDiCT-TB is a public-private partnership funded by the EU Innovative Medicines Initiative, comprising three major pharmaceutical partners (GSK, Sanofi, and Janssen), two biotechnology firms (ZF Screens and Microsens Medtech) and fifteen academic partners headed by the University of Liverpool. The multidisciplinary consortium brings together experts in microbiology, pharmacology, engineering, mathematical modelling, and clinical trials to create a new integrated framework for TB drug development, making optimal use of preclinical information to design the most efficient clinical trials. Visit for more information

The CPTR initiative is a comprehensive coalition dedicated to advancing development of safer, more effective, and faster-acting therapies for both drug-sensitive and drug-resistant TB. Co-founded by the Bill & Melinda Gates Foundation, the Critical Path Institute, and the Global Alliance for TB Drug Development, this public-private partnership includes virtually all pharmaceutical companies with compounds in clinical trial or in development, along with researcher partners and global regulatory agencies. Visit for more information

At a first ever IMI – C-Path co-sponsored conference in Brussels earlier this month, both consortia paved the way for the memorandum of understanding by sharing ideas and resources that could significantly strengthen the fight against TB. Initial priorities include building a comprehensive database of TB clinical trials and developing more effective modelling approaches using preclinical and clinical data. This new partnership marks an unprecedented global scientific effort across the public and private sectors to bring innovative and integrated approaches to the science underpinning the development of new drugs in tuberculosis and accelerate their arrival in the clinic.


The Critical Path Institute (C-Path) is an independent, non-profit organization established in 2005 with public and private philanthropic support from the Arizona community, Science Foundation Arizona and the U.S. Food and Drug Administration (FDA). An international leader in forming collaborations, C-Path has established global, public-private partnerships that currently include more than 1,000 scientists from government regulatory agencies, academia, patient advocacy organizations and dozens of major pharmaceutical companies. C-Path is headquartered in Tucson, Ariz., and has an office in Rockville, MD. Visit for more information.

IMI is the world’s largest public-private partnership in health. IMI is improving the environment for pharmaceutical innovation in Europe by engaging and supporting networks of industrial and academic experts in collaborative research projects. The European Union contributes €1 billion to the IMI research programme, and this is matched by in kind contributions worth at least another €1 billion from the member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The Innovative Medicines Initiative currently supports 40 projects, many of which are already producing impressive results. The projects are all working to address the biggest challenges in drug development to accelerate the development of safer and more effective treatments for patients. Visit for more information.
PreDiCT-TB receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115337, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.

Consortium Partners

PreDiCT-TB brings together twenty-one leading European research partners in tuberculosis from both Industry and Academia

View More

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115337, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.

The communication contained within this site reflects the author’s view and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained therein.